Linda Mileshkin
The University of Melbourne · 607 works · 32,778 citations · h-index 74
Top works
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- The repertoire of mutational signatures in human cancer
- Pan-cancer analysis of whole genomes
- Whole–genome characterization of chemoresistant ovarian cancer
- Cervical cancer: A global health crisis
- Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
- The evolutionary history of 2,658 cancers
- Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
- Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
- Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
- Patterns of somatic structural variation in human cancer genomes
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
- Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
- Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
- Longer Consent Forms for Clinical Trials Compromise Patient Understanding: So Why Are They Lengthening?
- EP073/#565 Survival and patterns of failure in small cell neuroendocrine carcinoma of cervix treated with definitive chemoradiotherapy